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Abstract
Plasmodium chabaudi infection induces a rapid and intense splenic CD4
+ T cell response that contributes to both disease
pathogenesis and the control of acute parasitemia. The subsequent development of clinical immunity to disease occurs
concomitantly with the persistence of low levels of chronic parasitemia. The suppressive activity of regulatory T (Treg) cells
has been implicated in both development of clinical immunity and parasite persistence. To evaluate whether IL-2 is required
to induce and to sustain the suppressive activity of Treg cells in malaria, we examined in detail the effects of anti-IL-2
treatment with JES6-1 monoclonal antibody (mAb) on the splenic CD4
+ T cell response during acute and chronic P. chabaudi
AS infection in C57BL/6 mice. JES6-1 treatment on days 0, 2 and 4 of infection partially inhibits the expansion of the
CD4
+CD25
+Foxp3
+ cell population during acute malaria. Despite the concomitant secretion of IL-2 and expression of high
affinity IL-2 receptor by large CD4
+ T cells, JES6-1 treatment does not impair effector CD4
+ T cell activation and IFN-c
production. However, at the chronic phase of the disease, an enhancement of cellular and humoral responses occurs in
JES6-1-treated mice, with increased production of TNF-a and parasite-specific IgG2a antibodies. Furthermore, JES6-1 mAb
completely blocked the in vitro proliferation of CD4
+ T cells from non-treated chronic mice, while it further increased the
response of CD4
+ T cells from JES6-1-treated chronic mice. We conclude that JES6-1 treatment impairs the expansion of Treg
cell population during early P. chabaudi malaria and enhances the Th1 cell response in the late phase of the disease.
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Introduction
The asexual blood stages of the Plasmodium ssp. are responsible
for the pathology and morbidity caused by malaria, an infectious
disease that remains a major devastating illness afflicting 350 to
500 million people annually and resulting in more than 1 million
deaths per year [1]. Among the cell populations involved in the
immune response to the blood stages of malaria, effector Th1 cells
are thought to play a key role in both disease protection and
pathogenesis [2,3,4]. Thus, an appropriate regulatory balance
between protective immune responses and immune mediated
pathology is required for a favorable outcome of infection [5]. The
suppressive activity of regulatory T (Treg) cells has been implicated
in the development of clinical immunity to disease known as
premunition, which occurs concomitantly with persistence of low
parasite burdens rather than sterilizing immunity [5]. However,
despite their relevance, the molecular pathways required to induce
and to sustain the suppressive activity of Treg cells in malaria are still
poorly characterized.
In the blood stage malaria caused by the rodent parasite,
Plasmodium chabaudi, the spleen CD4
+ T cell population expands
quickly, secretes considerable amounts of interferon-c (IFN-c) and
helps B cells to produce high quantities of polyclonal immuno-
globulin (Ig) M and IgG2a [6,7,8]. Both IFN-c [9] and acute phase
antibodies [10] have been implicated in the initial control of the
parasite. Effector Th1 cells also contribute to pathogenesis in acute
P. chabaudi malaria because mice lacking IFN-c or deprived of this
cell population have attenuated symptoms [11]. As the disease
progresses, the majority of lymphocytes activated during early
infection are eliminated by apoptosis [12], giving the opportunity
to the development of a large pool of effector-memory CD4
+
T cells that cooperate with B cells in the production of para-
site-specific high-affinity antibodies and have the capacity to
secrete IFN-c upon stimulation [13]. Similar to humans infected
with Plasmodium falciparum, the development clinical immunity to
P. chabaudi malaria occurs simultaneously with persistence of
low levels of chronic parasitemia [14], and Treg cells have also
been implicated in both processes [5]. The cooperation between
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required for complete parasite clearance after 2–3 months of
infection and also for acquisition of full protective immunity against
reinfection [14,15].
In contrast to the many studies addressing the role of CD4
+ T
cells in protection against P. chabaudi malaria, little is known about
the molecular mechanisms responsible for CD4
+ T cell prolifer-
ation,differentiationandregulation.IL-2hasmultipleandopposing
activities contributing to both the induction and the control of
immune responses [16,17]. Both activated and regulatory CD4
+ T
cells express CD25, the a chain of the high-affinity IL-2 receptor
(IL-2R) that combines with the IL-2R b chain (CD122) and the
common c chain (cc or CD132). While activated CD4
+ T cells can
produce their own IL-2, Treg cells depend on paracrine IL-2 for
their generation and maintenance and for the exertion of their
suppressive functions [18]. Thus, although IL-2 was first identified
as a potent T cell growth factor [19] that also displays pro-apoptotic
activity [20], the main non-redundant activity of IL-2 is to promote
T cell tolerance and homeostasis [21,22]. Moreover, IL-2 is
required for effector Th1 and Th2 cell differentiation, provides a
competitive advantage to T cells, resulting in optimal survival and
performance of memory cells, and inhibits the development of
inflammatory Th17 cells [16].
In the present study, we analyzed in detail the effects of anti-IL-
2 treatment with JES6-1 monoclonal antibody (JES6-1 mAb) on
the CD4
+ T cell response to P. chabaudi. This mAb has been shown
to block the CD8
+ T cell response to IL-2 in vitro via the low-
affinity IL-2R bc, apparently for biding to an IL-2 site that is
crucial for interaction with CD122 but less crucial for binding to
CD25 (high-affinity IL-2Rabc) [23]. Because IL-2 bound to JES6-
1 mAb has extended in vivo half-time and retains the ability to
interact with the high-affinity IL-2R, injection of a premixed 2:1
molar ratio of IL-2/JES6-1 mAb complexes has been used to
potentiate IL-2 signaling and induce expansion of the Treg cell
population [24]. Thus, analyzing the effects of JES6-1 treatment
on P. chabaudi malaria contributes to the efforts to understand the
molecular mechanisms responsible for activation and regulation of
the CD4
+ T cell response to Plasmodium aiming to ameliorate the
outcome of the disease.
Results
Expression of IL-2R a (CD25) and b (CD122) chains in the
splenic CD4
+ T cell response to P. chabaudi malaria
The infection of C57BL/6 mice with 10
6 parasitized red blood
cells (PRBC) resulted in a rapid increase in splenic CD4
+ T cell
numbers, attaining maximum levels concomitant with the peak of
parasitemia on day 7 post-infection (p.i.) (Fig. 1A). The increase of
the CD4
+ T cell population was accompanied by intense pro-
liferation and culminated in a prominent but short-lasting peak of
IFN-c production (Fig. 1B). As recently shown, the great majority
of proliferating and IFN-c-producing CD4
+ cells in the spleen
during the early infection are class II MHC-restricted CD4
+ T
cells and not NKT cells [13]. On day 10 p.i., in parallel with the
control of parasitemia, CD4
+ T cell numbers per spleen abruptly
decreased to values lower than those of non-infected mice (Fig. 1A).
The normalization of this population occurred concomitantly with
a second wave of CD4
+ T cell proliferation that peaked on day 20
p.i. and decreased thereafter (Fig. 1B).
Along with the proliferative response to infection, there was a
notable increase in CD122 expression, which gave evidence of two
different CD4
+ T cell subsets (Fig. 1C). The CD25
+CD122
+ subset
reached its maximum on days 4 and 7 p.i. before decreasing. The
CD25
2CD122
+ subset appearedlater, being first observed on day 7
p.i. and still detectable on days 15 p.i. (data not shown) and 30 p.i.
when it corresponded to 13.6% and 8.1% of CD4
+ T cells,
respectively. On day 7 p.i., both CD4
+CD122
+ cell populations had
a large size, whereas the majority of CD4
+CD25
+CD122
2 cells
were smaller (Fig. 1D). CD4
+CD25
+CD122
+ cells from 4-day
infected mice and CD4
+CD25
2CD122
+ cells from 15-day infected
mice were also large, whereas CD4
+CD25
+CD122
2 cells from
30-day infected mice were smaller (data not shown). As expected,
CD4
+CD25
+CD122
LO/- cells, a phenotype characteristic of Treg
cells, were also observed in non-infected mice. These results show
that splenic CD4
+ T cells that respond to acute P. chabaudi malaria
express the IL-2R b chain, but only a subset co-express the a chain.
During chronic infection, the majority of activated CD4
+ T cells
present only the IL-2R b chain.
Secretion of IL-2 and expression of activation markers by
splenic CD4
+ T cells during P. chabaudi malaria
Concomitantly with the high expression of IL-2R, the
percentages of IL-2-secreting CD4
+ T cells progressively increased
from day 3 to 7 p.i., decreasing to levels similar to those of non-
infected mice on day 15 p.i. (Fig. 2A). IL-2-secreting CD4
+ T cells
were large in size and expressed high amounts of CD25 and
CD122 (Fig. 2B). The majority of large CD4
+CD25
+ cells in 7-
day infected mice produced IL-2 (Fig. 2C). Small CD4
+CD25
+
cells had a phenotype typical of Treg cells in both groups of mice.
When compared to CD4
+CD25
2 cells, these cells expressed
significantly higher levels of mTGF-b, CTLA-4 and GITR,
slightly higher levels of CD122 and lower levels of CD45RB. In
contrast, large CD4
+CD25
+ cells had a phenotype characteristic of
activated cells, differing from small CD4
+CD25
+ cells by the
extremely high expression of CD122, CD45RB and CTLA-4.
These results show that IL-2 is produced during acute P. chabaudi
malaria by large CD4
+ T cells that express high levels of IL-2R,
together with several other activation markers.
Effects of JES6-1 treatment on the early CD4
+ T cell
response to P. chabaudi malaria
C57BL/6 mice treated with JES6-1 monoclonal antibodies
(mAb) on days 0, 2 and 4 p.i. with 10
6 PRBC were analyzed
according to expression of IL-2Ra and b chains and the activation
markers CD69 (early activation-induced C-type lectin) and CD44
(cell-cell contact adhesion molecule). The production of IL-17 was
also evaluated because anti-IL-2 treatment could shift the immune
response towards the Th17 profile, due to the negative control
exerted by IL-2 over development of inflammatory Th17 cells
[16]. Based on the percentages of CD4
+ cells showing high
expression of CD122, CD25, CD69 and CD44 and large size,
JES6-1 mAb had negligible effects on CD4
+ T cell activation with
only a minor inhibition of CD25 expression (Fig. 3A). The
cytokine pattern of CD4
+ T cells responding to acute infection
remained unchanged where the production of IFN-c predomi-
nated over IL-17 secretion (Fig. 3B). Nevertheless, JES6-1 treat-
ment resulted in a significant increase in basal (non-stimulated)
IFN-c production by CD4
+ T cells in both non-infected mice and
7-day infected mice. The CD4
+ T cell numbers per spleen
(Fig. 3C) and the capacity to control parasitemia (data not shown)
were not affected by JES6-1 treatment. Therefore, we also
evaluated the in vitro effects of the JES6-1 mAb on PRBC-
stimulated CD4
+ T cell proliferation. Cells obtained on day 4 p.i.
were analyzed because this is the peak of the in vitro proliferative
response to PRBC during acute infection [13]. As observed in vivo,
the JES6-1 mAb had no inhibitory effect on in vitro CD4
+ T cell
proliferation (Fig. 3D). These results show that JES6-1 treatment
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+ T cell activation, proliferation
and IFN-c production during acute P. chabaudi malaria.
Effects of JES6-1 treatment on the CD4
+CD25
+FoxP3
+ cell
population during P. chabaudi malaria
The expression of FoxP3 was evaluated in splenic CD4
+CD25
+
cells from C57BL/6 mice on days 7 and 20 p.i. with 10
6 PRBC.
In non-infected mice, the great majority of CD4
+CD25
+ cells
expressed FoxP3, a phenotype characteristic of Treg cells (Fig. 4A).
On day 7 p.i., although the majority of large cells were comprised
in the CD4
+CD25
+FoxP3
2 subpopulation, there was an increase
of 69.3% in the large CD4
+CD25
+FoxP3
+ subpopulation. When
considering cell number per spleen, there was a 3-fold increase in
the CD4
+CD25
+FoxP3
+ cell population on day 7 p.i. followed by a
reduction of 40.7% by day 20 p.i. (Fig. 4B). JES6-1 treatment
partially reduced CD4
+CD25
+FoxP3
+ cell numbers per spleen in
non-infected and 7-day infected mice. The involvement of IL-2
in the maintenance/expansion of the Treg cell population was
also evidenced by data showing a significant decrease in CD4
+
CD25
+FoxP3
+ cell percentages in non-infected and 7-day infected
mice treated with JES6-1 mAb compared to non-treated controls.
Effects of JES6-1 treatment on CD4
+ T cell phenotype and
proliferative response during chronic P. chabaudi malaria
Because IL-2 secreted during acute P. chabaudi malaria might
influence the late phase of the immune response either directly or
through its effects on Treg cells, we evaluated the effects of JES6-1
treatment on the CD4
+ T cell phenotype and proliferative response
on days 20 and 30 p.i., respectively. These time points coincided
with the peak and the end of the second wave of CD4
+ T cell
proliferation, respectively (Fig. 1B). Twenty days after the
beginning of JES6-1 treatment, there was no significant difference
in CD4
+ T cell numbers per spleen between non-infected mice and
infected mice (datanotshown).However, JES6-1treatment resulted
in additive increases in percentages of CD4
+CD62L
LOCD45RB
LO
(effector-memory) cells and CD4
+CD69
+ (activated) cells (Fig. 5A
and 5B). Mice treated with anti-bgalactosidase isotype control
(GL117 mAb) did not differ from non-treated mice (data not
shown). Non-stimulated (basal) and PRBC-stimulated CD4
+ T cell
proliferation was also increased in JES6-1-treated mice, a pheno-
menon observed in non-infected and infected mice (Fig. 5C). The
CD8
+ T cell proliferation in response to PRBC was also enhanced
in both groups of JES6-1-treated mice (3.760.1% and 13.061.6%
of CSFE
LO cells, p,0.05) compared to non-treated mice (1.96
0.1% and 4.860.4% of CSFE
LO cells). Moreover, JES6-1 mAb
completely blocked the PRBC-stimulated proliferation of CD4
+ T
cells from non-treated mice, while it further increased the response
of CD4
+ T cells from JES6-1-treated mice. These results show that
JES6-1 treatment enhances the CD4
+ T cell response during the
chronic phase of P. chabaudi infection.
Effects of JES6-1 treatment on the development of
protective immunity to P. chabaudi malaria
Because CD4
+ T cells developed in JES6-1-treated mice have
an improved capacity to proliferate when stimulated with PRBC,
we sought to verify the effects of in vivo JES6-1 treatment on the
Figure 1. Expression of IL-2R a and ß chains in splenic CD4
+ T cells during P. chabaudi malaria. (A) Parasitemia curves and CD4
+ T cell
numbers per spleen were evaluated in C57BL/6 mice infected with 10
6 PRBC (mean 6 SD, n=4). (B) Basal (non-stimulated) proliferation and IFN-c
production in infected mice. Percentages of replicating (CSFE
LO) CD4
+ T cells and CD4
+IFN-c
+ cells are shown (mean 6 SD, n=4). (C) On days 4, 7 and
30 p.i., CD25 and CD122 expression was analyzed in gated CD4
+ T cells. Numbers inside dot plots refer to means 6 SD (n=3–4) of cell percentages in
each gate. (D) On day 7 p.i., CD25
2CD122
+, CD25
+CD122
+, CD25
2CD122
2 and CD25
+CD122
2 cells in gated CD4
+ T cells of the same groups of mice
were analyzed according to cell size (FSC). Numbers inside histograms refer to means 6 SD (n=3–4) of large cell percentages. In A–D, *p,0.05,
compared to non-infected mice (day 0). Dot plots and histograms show a representative mouse of each group. Data are representative of three
separate experiments.
doi:10.1371/journal.pone.0029894.g001
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IgG2a. In general, JES6-1 treatment increased the non-stimulated
(basal) and PRBC-stimulated TNF-a and IFN-c production in
both non-infected and 30-day infected mice (Fig. 6A). However,
there was no effect on PRBC-stimulated TNF-a secretion by
spleen cells from non-infected mice and PRBC-stimulated IFN-c
secretion by spleen cells from 30-day infected mice. On day 30 p.i.,
the serum titers of parasite-specific IgG2a were significantly higher
in JES6-1-treated mice compared to non-treated mice (Fig. 6B).
Interestingly, similar levels of PRBC-stimulated TNF-a and IFN-c
production and parasite-specific IgG2a were found in non-treated
30-day infected mice and in JES6-1-treated non-infected mice.
Both JES6-1-treated and non-treated infected mice efficiently
controlled a secondary challenge with 10
8 PRBC given on day 30
p.i. (data not shown). Additionally, mice injected with spleen cells
from 30-day infected mice showed lower parasitemia peaks
following infection when cells were taken from JES6-1-treated
mice (Fig. 6C). We concluded that JES6-1 treatment enhances the
Th1 cell response, leading to increased production of TNF-a and
parasite-specific IgG2a antibodies and optimizing the protective
immunity to P. chabaudi malaria.
Discussion
We have recently proposed that the splenic CD4
+ T cell
response to blood stages of P. chabaudi malaria develops in two
consecutive phases where conventional CD4
+ T cells are the main
protagonists [13]. The early phase of the response may establish a
bridge between innate and acquired immunity, as it rapidly
provides large amounts of proinflammatory cytokines and help B
cells to secrete polyclonal Ig. The late phase of the response
generates a large pool of effector-memory CD4
+ T cells that
cooperate with B cells in the production of parasite-specific
high-affinity antibodies and have the capacity to secrete IFN-c
upon stimulation. In the present study, we examined in detail the
effects of JES6-1 treatment on the early and late phases of CD4
+ T
cell response to P. chabaudi infection.
Initially, we observed that IL-2 is produced during acute
infection by activated CD4
+ T cells expressing high levels of IL-2R
a and b chains, as well as the activation markers GITR, mTGF-b,
CTLA-4 and CD45RB. The consumption of IL-2 by activated
lymphocytes could explain the low levels of this cytokine detected
in culture supernatants from human and mouse with acute malaria
[8,25], an interference minimized in our analysis by using a bi-
functional anti-IL-2 mAb that binds to the cell surface and
competes with IL-2R for capturing the cytokine molecules soon
after their release into the extracellular milieu. Corroborating our
data, increased production of IL-2 was observed by intracellular
staining in blood CD4
+ T cells from acute malaria patients [26].
Moreover, intracellular IL-2 production coincides with increase of
Treg cell population in the spleen during P. chabaudi malaria [27].
The concomitant production of IL-2 and expression of high
affinity IL-2R by activated CD4
+ T cells during acute infection
implicates this cytokine as a participant in the immune response to
P. chabaudi malaria. The lack of effect of in vivo or in vitro JES6-1
treatment in the early CD4
+ T cell activation, proliferation and
IFN-c production, and consequently in the ability to control acute
parasitemia, can be explained by the high expression of CD25
since IL-2 bound to JES6-1 mAb retains the ability to interact with
the high-affinity IL-2R [23]. However, it is also possible that the
major role of IL-2 during the early CD4
+ T cell response to P.
chabaudi infection is to expand the Treg cell population, while the
effector CD4
+ T cell response is independent of IL-2. These
possibility is supported by data showing that IL-2 is not required
for the initial cycling of T cells, as suggested by previous studies
showing that T cell proliferation is not abrogated by anti-IL-2 or
Figure 2. Secretion of IL-2 and expression of activation markers by splenic CD4
+ T cells during P. chabaudi malaria. (A) IL-2 secretion
was analyzed in gated CD4
+ T cells obtained from C57BL/6 mice on days 3, 5, 7 and 15 p.i. with 10
6 PRBC. Numbers inside dot plots refer to means 6
SD (n=3–4) of cell percentages in the upper right gate. (B) Cell size (FSC) and expression of CD25 and CD122 were evaluated in gated CD4
+IL-2
2 and
CD4
+IL-2
+ cells of the same groups of mice. (C) On day 7 p.i., CD122, mTGF-b, CD45RB, CTLA-4 and GITR expression was analyzed in gated CD4
+CD25
+
cells, subdivided into small and large cells. Numbers inside dot plots refer to means 6 SD (n=3–4) of cell percentages in each gate. The mean
fluorescence intensity (MFI) of CD4
+CD25
2 cells (controls) stained with mAb to mTGF-ß and GITR was comparable to respective isotopic controls
(data not shown). In A–C, there was a significant difference (*p,0.05) between experimental conditions and non-stimulated (NS) cells from non-
infected mice. Cells from non-infected mice stimulated with anti-CD3 mAb were used as positive controls. Dot plots and histograms show a
representative mouse of each group. Data are representative of three separate experiments.
doi:10.1371/journal.pone.0029894.g002
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receptor (TCR) [28,29]. Moreover, several studies using IL-2- or
IL-2R-deficient mice clearly indicate that T cell activation and
proliferation occur in vitro and in vivo independently of all cc-
dependent cytokines but are dependent on TCR and costimula-
tory signals [30,31,32,33].
In agreement with this notion, it has been previously shown that
T cell immunity to P. chabaudi [34], as well as to other infectious
pathogens [35], can be generated in the absence of IL-2. Thus, it is
reasonable that intense costimulation makes IL-2 dispensable for T
cell activation, a suitable possibility if we consider that IL-2R and
the CD28, ICOS and OX40 costimulatory receptors relay
intracellular signals through phosphoinositide 3-kinases (PI3K),
which culminate in a broad variety of cell biological effects,
including proliferation and cytokine synthesis [36]. Accordingly,
unpublished data from our laboratory revealed the high expression
of ICOS and OX40 during the early CD4
+ T cell response to P.
chabaudi malaria (Castillo-Me ´ndez et al., manuscript in preparation).
The abundance of costimulatory signals could also cooperate to
inactivate Treg cells [37] and consequently enlarge the spectrum
of CD4
+ T cell specificities involved in the early response to
infection.
The idea that Treg cell inactivation contributes to the early
CD4
+ T cell response to infection is indirectly supported by our
data showing a massive response to parasites in non-infected mice
a month after JES6-1 treatment, a condition where Treg cells may
have been inactivated by IL-2 deprivation. This increased CD4
+ T
cell response to parasites in JES6-1-treated non-infected mice
occurs in terms of both PRBC-stimulated proliferation and IFN-c
production. The mechanism triggering robust CD4
+ T cell
response to PRBC a month after JES6-1 treatment of non-
infected mice is currently been investigated by our research group.
Our working hypothesis is that depletion of Treg cell population
due to IL-2 inhibition results in a long-lasting deficiency in the
ability to regulate the immune system, leading to CD4
+ T cell
hyperresponsiveness to PRBC. Although the number of Treg cells
per spleen was reestablished on day 20 p.i., the reduced expression
of regulatory molecules, such as CTLA-4 and PD-1, may impair
their suppressive activity.
The increase in Treg cell population has been previously
reported in P. chabaudi and Plasmodium yoelii infections [38,39], but
its implication in the control of immune responses to malaria is
still a matter of debate [5]. Our data extend these findings by
showing that IL-2 is partially required for expanding the CD4
+
Figure 3. Effects of JES6-1 treatment on the early CD4
+ T cell response to P. chabaudi malaria. (A) C57BL/6 mice were treated with JES6-1
mAb on days 0, 2 and 4 p.i. with 10
6 PRBC. On day 7 p.i., splenic CD4
+ T cells were analyzed for CD122, CD25, CD69 and CD44 expression and cell size
(FSC). Data show gated CD4
+ T cells expressing high levels of activation markers and large size (n=3–4). (B) Non-stimulated (basal) and anti-CD3 mAb
stimulated IFN-c and IL-17 production was evaluated in CD4
+ T cells from the same groups of mice. (C) Numbers of CD4
+ T cells per spleen were
determined in the same groups of mice. (D) On day 4 p.i., PRBC-stimulated CD4
+ T cell proliferation was analyzed in vitro in the presence or absence
of JES6-1 mAb. Histograms show CFSE fluorescence in gated CD4
+ T cells. The means 6 SD (n=3–4) of the percentages of replicating (CFSE
LO) cells
are shown. In A–D, significant differences compared experimental conditions *p,0.05 with cells from non-infected (NI) mice; **p,0.05 with cells
from non-treated (NT) mice; and #p,0.05 with non-stimulated cells. Data are representative of three separate experiments.
doi:10.1371/journal.pone.0029894.g003
Anti-IL-2 Treatment in Plasmodium chabaudi Malaria
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+CD25
+FoxP3
+ cell population during P. chabaudi malaria. (A) C57BL/6 mice
were infected with 10
6 PRBC. On day 7 p.i., CD4
+ T cells were analyzed for CD25 and FoxP3 expression and cell size (FSC). Dot plots represent gated
CD4
+ T cells. Dot plots and histograms show a representative mouse from each group. Numbers inside dot plots refer to means 6 SD (n=4) of cell
percentages in each gate. Histograms show gated CD4
+CD25
+FoxP3
+ and CD4
+CD25
+FoxP3
2 cells in relation to CD4
+CD25
2FoxP3
2 cells. Numbers
inside histograms refer to means 6 SD (n=4) of large cell percentages. (B) On days 0, 2 and 4 p.i., C57BL/6 mice were treated with JES6-1 mAb. Data
represent the means 6 SD (n=4) of CD4
+CD25
+FoxP3
+ cell percentages and numbers per spleen on days 7 and 20 of infection. In A–B, significant
differences compared experimental conditions *p,0.05 with cells from non-infected (NI) mice; **p,0.05 with cells from non-treated (NT) mice; and
#p,0.05 with CD25
+FoxP3
+ cells. Data are representative of two separate experiments.
doi:10.1371/journal.pone.0029894.g004
Figure 5. Effects of JES6-1 treatment on splenic CD4
+ T cell phenotype and proliferative response to PRBC during chronic P.
chabaudi malaria. (A) C57BL/6 mice were treated with JES6-1 mAb on days 0, 2 and 4 p.i. with 10
6 PRBC. On day 20 p.i., CD62L and CD45RB
expression was evaluated in gated CD4
+ T cells. Numbers inside dot plots refer to means 6 SD (n=3–4) of cell percentages in each gate. (B) CD69
expression was analyzed in gated CD4
+ T cells from the same groups of mice. (C) In vitro proliferative response of PRBC-stimulated CD4
+ cells cultured
in the presence or absence of JES6-1 mAb. CD4
+ T cells were obtained from 30-day infected mice treated in vivo or not with JES6-1 mAb on days 0, 2
and 4 of infection. Histograms show CFSE fluorescence in gated CD4
+ T cells. The means 6 SD (n=3–4) of the percentages of replicating (CFSE
LO)
cells are shown. In A–C, significant differences compared experimental conditions *p,0.05 with cells from non-infected (NI) mice; **p,0.05 with non-
treated (NT) mice or cells; and # p,0.05 with non-treated (NT) cells from JES6-1-treated mice. Data are representative of two separate experiments.
doi:10.1371/journal.pone.0029894.g005
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+FoxP3
+ cell population during P. chabaudi malaria. The fact
that some increase in CD4
+CD25
+FoxP3
+ cell numbers per spleen
still occurred in acutely infected JES6-1-treated mice could also be
related to the abundance of costimulatory signals, which have been
implicated in Treg cell development and peripheral homeostasis
[40]. It is worth noting that, in our analysis, the impaired increase in
CD4
+CD25
+FoxP3
+cell numbers duetoJES6-1treatmentdoesnot
significantly affect the early CD4
+ T cell response to parasites, as the
only difference observed after JES6-1 treatment in acutely infected
mice is a slight augmentation of IFN-c production.
The effects of JES6-1 treatment in vitro drastically change during
the infection in which inhibition of CD4
+ T cell response to
parasites is observed at the chronic phase of the disease, but not at
the acute phase as discussed above. The results showing the ability
of JES6-1 mAb to block in vitro CD4
+ T cell proliferation at the
chronic infection demonstrate the effectiveness of this treatment to
completely inhibit IL-2 signaling. This shift could be a conse-
quence of the reduction of PI3K-mediated costimulatory signals
leading to IL-2 dependency. This process could involve IL-2
induced expression of regulatory molecules, such as PD-1 and
CTLA-4, in CD4
+ T cells [41,42]. This would increase the
threshold for TCR signaling and, as a consequence, restrain the
spectrum of CD4
+ T cell specificities involved in the response and
provide an IL-2 driven competitive advantage to parasite-specific
CD4
+ T cells [43]. IL-2 dependency may also allow the control of
self (cross) reactive clones by Treg cells, which are thought to
operate by scavenging this cytokine [18,44].
The expansion of Treg cell population during the early CD4
+ T
cell response to infection may be essential for the development of a
cohort of Treg cells shaped to modulate the pool of effector-
memory and memory CD4
+ T cells generated during the late
phase of the response, by skewing their specificity repertoire
towards the recognition of parasite-specific peptides and avoiding
the expansion of self (cross) reactive clones. The Treg cell
population was still increased on day 20 p.i. indicating that
proliferating Treg cells were not eliminated after acute infection.
Treg cell inactivation during the acute infection may explain the
enhancement of cellular and humoral responses in JES6-1-treated
mice during the chronic infection, which results in the improved
capacity of spleen cells to transfer protection to naı ¨ve mice. Spleen
cells from JES6-1-treated mice conferred a substantial protection
(,40% reduction in parasitemia) if we consider the high parasite
inoculum used in mouse challenge, and we can envisage that
concomitant treatment with additional immunotherapies such as
anti-IL-10 mAb could further improve parasite control.
Another possible explanation for the increase of immune
response in JES6-1-treated chronic mice is related to the fact
that, in some particular conditions, IL-2/JES6-1 mAb complexes
can potentiate IL-2 signaling and amplify the effector T cell
function [24]. Although this phenomenon is observed following
administration of premixed 2:1 molar ratio of IL-2/JES6-1 mAb
complexes, the possibility that similar conditions occur in vivo
cannot be discarded. It should be noted, however, that in our
experiments JES6-1 treatment results in substantial CD4
+ T cell
activation in non-infected mice, whereas IL-2/JES6-1 treatment
leads to expansion of the Treg cell population and, in consequence,
to reduction of CD4
+ and CD8
+ T cell responses to Plasmodium
berghei infection [24] and to increase in parasitemia during P.
chabaudi infection [27]. These opposite effects indicate that JES6-1
mAb is responsible for very different outcomes when administered
alone or coupled with two molecules of IL-2, an artificial condition
that may cause the approximation of two IL-2Ra chains and result
in cell signaling independent of the b chain.
This work reinforces the idea that the CD4
+ T cell response to
P. chabaudi malaria develops in two distinct phases wherein JES6-1
treatment impairs the expansion of Treg cell population at the early
phase and enhances the Th1 cell response at the late phase. This
study may help to understand the molecular mechanisms involved
in the immune response to Plasmodium and contribute to efforts
aiming to manipulate this response to ameliorate the outcome of
the disease.
Materials and Methods
Mice, parasites and infection
Six to eight-week-old C57BL/6 female mice were bred under
pathogen-free conditions at the Isogenic Mice Facility, ICB-USP,
Sa ˜o Paulo, Brazil. Plasmodium chabaudi AS was maintained as
previously described [9]. Mice were infected intraperitoneally and
parasitemias were determined by microscopic examination of
Giemsa stained blood smears.
Ethics Statements
All procedures were in accordance with national regulations of
ethical guidelines for mice experimentation and welfare of the
conselho nacional de sau ´de and cole ´gio brasileiro em experi-
Figure 6. Effects of JES6-1 treatment on the regulation of acquired immune responses to P. chabaudi malaria. (A) C57BL/6 mice were
treated with JES6-1 mAb on days 0, 2 and 4 p.i. with 10
6 PRBC. On day 30 p.i., TNF-a and IFN-c production was evaluated in spleen cell supernatants
(mean 6 SD, n=4). (B) Serum titers of parasite-specific IgG2a were determined in the same groups of mice. (C) Parasitemia curves were evaluated in
C57BL/6 mice injected with spleen cells from JES6-1-treated mice and non-treated (NT) mice on day 30 p.i. and challenged with 10
8 PRBC (mean 6
SD, n=4). In A–B, significant differences compared experimental conditions *p,0.05 with non-infected (NI) mice; and **p,0.05 with non-treated (NT)
mice. In C, significant differences compared to experimental conditions *p,0.05 with mice transferred with cells from non-treated (NT) mice. Data are
representative of two separate experiments.
doi:10.1371/journal.pone.0029894.g006
Anti-IL-2 Treatment in Plasmodium chabaudi Malaria
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29894mentac ¸a ˜o animal (cobea), brazil, the protocols being approved by
the health animal comitte (comissa ˜o de e ´tica no uso de animais -
ceua - icb/usp) of the instituto de cie ˆncias biome ´dicas of the
universidade de sa ˜o paulo, sa ˜o paulo, brazil, qith permit number
0019/2005 and 0036/2007.
Anti-IL-2 mAb treatment
Mice were treated intraperitoneally with rat anti-IL-2 (JES6-
1A12) mAb (1 mg/mouse/day) on days 0, 2 and 4 of infection.
Spleen cells were cultured in vitro with 0.2 mg/ml anti-IL-2 mAb.
Spleen cell suspensions
Spleen cells were cultured in RPMI 1640 supplemented with
penicillin (100 U/ml), streptomycin (100 mg/ml), 2-mercaptoeth-
anol (50 mM), L-glutamine (2 mM), sodium pyruvate (1 mM) and
3% heat-inactivated fetal calf serum (FCS). All supplements were
purchased from Life Technologies. Cell numbers were determined
with a Neubauer chamber.
Spleen cell phenotyping
Spleen cells (1610
6) were stained with FITC-, PE-, PerCP- or
APC-labeled mAb to CD4 (H129.19), CD25 (PC61), CD45RB
(16A), CD62L (MEL-14), CD122 (TMb1), CD69 (H1-2F3), CD44
(IM7) and CTLA-4 (UC-4F10-11) from BD Pharmingen.
Biotinylated mAb to mTGF-b (G766B) from Promega was
detected with FITC-labeled streptavidin (BD Pharmingen).
Unlabeled mAb to GITR (108619) from RD System was detected
with FITC-labeled polyclonal anti-rat Ig from BD Pharmingen.
Cells were analyzed by flow cytometry using a FACScalibur with
CELLQUEST software (Becton Dickinson). The percentages of
large cells were determined by analyzing forward light scatter
(FSC), using gates defined in histograms of non-activated
splenocytes.
Intracellular staining of Foxp3
Spleen cells (1610
6) were stained with anti-CD4 mAb and fixed
with Cytofix/Cytoperm (BD Bioscience) for 30 min at room
temperature. Cells were permeabilized with 1% formaldehyde for
30 min, centrifuged and washed twice in PBS containing 5% FCS
and 0.1% NaN3. After incubation for 2 h with FITC conjugated
anti-mouse/rat Foxp3 mAb, cells were washed and analyzed by
flow cytometry.
IL-2 secretion assay
The IL-2 PE cytokine secretion assay was performed according
to the manufacturer’s recommendations (BD Biosciences). This
assay uses a bi-functional mAb capable of binding CD45 on one
arm and IL-2 on the other arm. Spleen cells (2610
6) were
incubated with the bi-functional mAb for 45 min at 37uCi n5 %
CO2. The presence of IL-2 bound to bi-functional mAb was
detected with PE-labeled anti-IL-2 mAb. As a positive control,
spleen cells (2610
6) from non-infected mice were cultured in vitro
for 3 h with anti-CD3 mAb (BD Pharmingen). The analyses were
performed by flow cytometry.
Proliferation assay
The proliferative CD4
+ cell response was measured as
previously described [45]. Briefly, 6610
6 cells/ml in PBS with
0.1% BSA were incubated with 5,6-carboxy fluorescein succini-
midyl ester (CFSE; Molecular Probes) at a final concentration of
5 mM for 20 min at 37uC. Cells (1610
6) were cultured in 96-well
plates (Costar) with PRBC (3610
6) or medium alone for 72 h at
37uCi n5 %C O 2. After incubation, cells were stained with PE-
labeled mAb to CD4 and analyzed by flow cytometry.
Multicytokine assessment
IFN-c and TNF-a were quantified simultaneously by a
cytometric bead array (CBA; BD Pharmingen) of supernatants
obtained from the same cultures used in the proliferation assay.
This technique uses flow cytometry to measure soluble analytes in
a particle-based immunoassay and was carried out according to
the manufacturer’s instructions (BD Pharmingen). The lower limit
of detection for all cytokines in this assay was 20 pg/ml.
Intracellular staining for IFN-c and IL-17
For intracellular IFN-c and IL-17, spleen cells (1610
6) were
cultured with GolgiStop overnight at 37uCi n5 %C O 2 according
to the manufacturer’s instructions (BD Pharmingen). After
washing, cells were surface stained with FITC- or Cy-Chrome-
labeled mAb to CD4 and CD8. Cells were then fixed with
Cytofix/Cytoperm buffer and incubated with PE-labeled mAb to
IFN-c and IL-17 diluted in Perm/Wash buffer. The analysis was
performed by flow cytometry.
Parasite-specific ELISA
Anti-P. chabaudi antibodies were quantified by ELISA as
previously described [46]. In brief, 96-well flat-bottom microtiter
plates (Costar) were coated overnight (4uC) with a total parasite
extract (8 mg/ml). Plates were saturated with 1% BSA (bovine
serum albumin) for 1 h. After washing, wells were incubated with
100 ml mouse serum (diluted from 1:50 to 1:6400) for 90 min at
room temperature. Assays were developed with goat anti-mouse
IgM or IgG2a peroxidase conjugated antibodies (Southern
Biotechnology Associates) for 1 h, followed by 100 ml/well of
TMB (tetra-methyl-benzidine) (Zymed) for 15 min, and the
absorbance was quantified with a Spectra Max 190 spectropho-
tometer (Molecular Devices) at 650 nm. The antibody level in
each serum sample was expressed as the reciprocal of the endpoint
titer, which was defined in serial dilutions as the lowest dilution
with a background optical density (O. D.).
Statistical analysis
Statistical analysis was generally performed with t-test and
Mann Whitney test using Graph Pad Prism 4 software. Differences
between two groups were considered significant when the p value
was ,0.05 (5%).
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